Online inquiry

IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4023MR)

This product GTTS-WQ4023MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4023MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ72MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ9340MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ7782MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GS-5745
GTTS-WQ15024MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ9764MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ14158MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ468MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ2540MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW